Axon Enterprise (NASDAQ:AXON) Given New $700.00 Price Target at Citizens Jmp

Axon Enterprise (NASDAQ:AXON) had its price objective reduced by Citizens Jmp from $825.00 to $700.00 in a research report report published on Thursday morning,Benzinga reports. Citizens Jmp currently has a market outperform rating on the biotechnology company’s stock.

AXON has been the subject of a number of other research reports. Barclays decreased their price objective on shares of Axon Enterprise from $702.00 to $682.00 and set an “overweight” rating for the company in a research report on Wednesday, February 25th. Craig Hallum restated a “buy” rating and issued a $820.00 price target on shares of Axon Enterprise in a research note on Wednesday, February 25th. Wall Street Zen raised Axon Enterprise from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Citigroup reissued a “buy” rating on shares of Axon Enterprise in a research note on Wednesday, February 25th. Finally, The Goldman Sachs Group set a $535.00 price target on shares of Axon Enterprise in a report on Thursday. Sixteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $712.75.

Axon Enterprise Trading Down 7.6%

AXON stock traded down $32.64 during trading on Thursday, hitting $394.25. The company had a trading volume of 1,045,698 shares, compared to its average volume of 1,060,959. Axon Enterprise has a 52-week low of $339.01 and a 52-week high of $885.91. The company has a 50 day simple moving average of $451.93 and a 200-day simple moving average of $527.52. The firm has a market capitalization of $31.77 billion, a P/E ratio of 158.16, a PEG ratio of 8.24 and a beta of 1.44. The company has a quick ratio of 2.29, a current ratio of 2.53 and a debt-to-equity ratio of 0.53.

Axon Enterprise (NASDAQ:AXON) last issued its earnings results on Wednesday, May 6th. The biotechnology company reported $1.61 EPS for the quarter, topping analysts’ consensus estimates of $1.60 by $0.01. Axon Enterprise had a net margin of 6.90% and a return on equity of 3.95%. The business had revenue of $807.35 million for the quarter, compared to the consensus estimate of $778.91 million. During the same period in the prior year, the firm earned $1.47 EPS. The company’s revenue for the quarter was up 33.7% compared to the same quarter last year. As a group, research analysts forecast that Axon Enterprise will post 1.41 earnings per share for the current fiscal year.

Insider Transactions at Axon Enterprise

In other Axon Enterprise news, Director Jeri Williams sold 157 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $490.00, for a total transaction of $76,930.00. Following the sale, the director directly owned 1,159 shares in the company, valued at $567,910. This represents a 11.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Patrick W. Smith sold 10,000 shares of Axon Enterprise stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $500.24, for a total transaction of $5,002,400.00. Following the completion of the transaction, the chief executive officer owned 3,090,997 shares of the company’s stock, valued at $1,546,240,339.28. This trade represents a 0.32% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 13,855 shares of company stock worth $7,109,828 in the last three months. Company insiders own 4.40% of the company’s stock.

Hedge Funds Weigh In On Axon Enterprise

Institutional investors and hedge funds have recently made changes to their positions in the stock. Creative Financial Designs Inc. ADV acquired a new position in shares of Axon Enterprise during the fourth quarter worth $28,000. Stone House Investment Management LLC purchased a new stake in Axon Enterprise in the 3rd quarter valued at $29,000. New Millennium Group LLC acquired a new stake in Axon Enterprise during the 3rd quarter worth $29,000. Sound Income Strategies LLC raised its stake in Axon Enterprise by 550.0% during the 4th quarter. Sound Income Strategies LLC now owns 52 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 44 shares during the last quarter. Finally, Camelot Portfolios LLC acquired a new stake in Axon Enterprise during the 4th quarter worth approximately $30,000. 79.08% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Axon Enterprise

Here are the key news stories impacting Axon Enterprise this week:

• Positive Sentiment: Q1 revenue and guidance lift: Axon reported Q1 revenue of ~$807M (up ~34% YoY) and raised FY revenue growth to 30%–32%, reiterating strong cash?flow targets—this underpins the case for durable growth. Axon reports Q1 2026 revenue of $807 million, up 34% year over year
• Positive Sentiment: AI & counter?drone acceleration: Management highlighted AI product revenue up ~700% and counter?drone bookings/revenue growing several hundred percent, helping drive the guidance raise and stronger bookings momentum. Axon Raises Guidance With AI Revenue Up 700%
• Positive Sentiment: Analyst support remains: Several firms maintained or raised bullish ratings (e.g., JPMorgan raised its price target), reflecting continued confidence in Axon’s growth runway. These notes can provide buying interest. Benzinga coverage of analyst actions
• Neutral Sentiment: Municipal order in Baltimore: The city approved a $153M police-equipment contract (body cameras, Tasers), which is incremental revenue and a commercial win but also drew competitive/price scrutiny that could attract political headlines. FOX45: Baltimore approves $153M contract for police equipment
• Neutral Sentiment: Mixed analyst notes and coverage: Media pieces emphasize bullish ARR/AI trends but also debate valuation — this creates two?sided flows as some investors buy the growth story while others sit on the sidelines. Analysts Conflicted on These Industrial Goods Names
• Negative Sentiment: Margin / EPS pressure: While revenue beat, some coverage flagged an EPS miss vs certain estimates and tariff?driven margin pressure — a reminder that profitability and cost headwinds matter to investors. AXON Q1 Earnings Miss Estimates on Tariff-Driven Margins
• Negative Sentiment: Short?term selling and valuation concerns: Despite the beat, shares have pulled back as some investors take profits after recent gains and others focus on a stretched P/E and several trimmed price targets — creating downward pressure. Assessing Axon Enterprise (AXON) Valuation After A Sharp Year To Date Share Price Decline

Axon Enterprise Company Profile

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.